TABLE 5.
Running clinical trial studies for validation of Lopinavir/Ritonavir (https://clinicaltrials.gov/ct 2/results).
| Sl. No. | Title | NCT No. | Therapeutic Dose | Phase | Location |
|---|---|---|---|---|---|
| 1 | Evaluation of combinatory effect Lopinavir/Ritonavir, Ribavirin and IFN-β against SARS-CoV-2 | NCT04276688 | Loading Dose: 400 mg, and 100 mg (Lopinavir/Ritonavir Day 1–14) BID, 400 mg (Ribavirin Day 1 -14, 0.25 mg Interferon (Day 1–3) | 2 | HongKong |
| 2 | Evaluation of Traditional Chinese Medicines against SARS-CoV-2 | NCT04251871 | Loading dose: Lopinavir (400 mg), ritonavir (100 mg) twice a day (2 weeks). | Not applicable | China |
| 3 | Clinical trial of Lopinavir/Ritonavir for hospitalized COVID-19 patients | NCT04315948 | Lopinavir/Ritonavir (200 mg). Lopinavir and ritonavir (50 mg) IFN-β-1a : 44 µg/0.5 ml (single dose) | 3 | France |